Abstract Library

#4481 Predicting peptide receptor radionuclide therapy (PRRT) response through the landscape of the immune microenvironment in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) often have poor prognosis upon metastasis. Peptide receptor radionuclide therapy (PRRT) is a novel treatment leveraging targeted cytotoxicity of radionuclides to efficiently address primary and metastatic tumours of NETs.

Conference:

Presenting Author: Yu J

Authors: Zeng Z, Lu M, Xie Q, Li J, Yang Z,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumour, tumour immune microenvironment, tumour response, therapeutic effect prediction,

#4421 Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,

#3808 Comparison of [18F]AlF-NOTA-JR11 with [68Ga]DOTA-JR11 PET/MRI in models, mice, and neuroendocrine tumor patients

Introduction: Compared with [68]Ga, [18]F has the advantages of high production yield, shorter positron range, and favourable half-life allowing for centralized production and distribution to distant centers.

Conference:

Presenting Author: Yu J

Authors: Ding X, Meng X, Xie Q, Yu J,

Keywords: [18F]AlF-NOTA-JR11, [68Ga]DOTA-JR11, neuroendocrine tumor, PET/MRI,

#3685 Somatostatin receptor imaging with difference positive rate of mice

Introduction: Majority of neuroendocrine neoplasms express SSTR2, and the pathological results of a single lesion cannot accurately reflect the expression of SSTR2 in other lesions because of heterogeneity.

Conference:

Presenting Author:

Authors: Qing X, Xiangxi M, Zhi Y, Jiangyuan Y,

Keywords: neuroendocrine neoplasm, somatostatin receptor, imaging, immunohistochemistry,

#3147 Synthesis, preclinical evaluation and a pilot clinical imaging study of [18F]AlF-NODA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE

Introduction: [68Ga]Ga (87% β+, 0.83Mev, T1/2=68min) is widely used associate with SSTR agonist and antagonist in molecular imaging of NETs. [18F]F (97% β+, 0.64Mev, T1/2=109min) has suitable half-life for peptide and lower β+-trajectory (

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Yu J

Authors: Yu J, X Q, Lu M, Li J, Y Z,

Keywords: neuroendocrine neoplasm, somatostatin receptor, [18F]AlF, JR11, TATE, PET imaging,